# Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/befotertinib-d-0316-versus-icotinib-as-first-line-therapy-for-patients-with-egfr/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Shun Lü,Jianying Zhou,Hong Jian,Lin Wu,Ying Cheng,Yun Fan,Jian Fang,Gongyan Chen,Zhihong Zhang,Dongqing Lv,Liyan Jiang,Rong Wu,Xiangming Jin,Xiaodong Zhang,Junhong Zhang,Conghua Xie,Gengyun Sun,Dongning Huang,Jiuwei Cui,Renhua Guo,Zhigang Han,Zhendong Chen,Jin Liang,Wu Zhuang,Xingsheng Hu,Aimin Zang,Yi Zhang,Shundong Cang,Yuanbo Lan,Xi Chen,Laiyu Liu,Xingya Li,Jun Chen,Rui Ma,Yanzhen Guo,Ping Sun,Panwen Tian,Yueyin Pan,Zhe Liu,Peiguo Cao,Lieming Ding,Yang Wang,Xiaobin Yuan,Pengxiang Wu |
| Citations | 72 |
| DOI | 10.1016/s2213-2600(23)00183-2 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4377969083 |
| PMID | 37244266 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Xingsheng Hu](https://scholariq.org/researchers/xingsheng-hu/)
- [Hong Jian](https://scholariq.org/researchers/hong-jian/)

## Paper journal

- [The Lancet Respiratory Medicine](https://scholariq.org/journals/the-lancet-respiratory-medicine/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.